Papillary thyroid carcinoma (PTC) is the most common malignant thyroid tumour representing 80--90% of all thyroid malignancies ([@bib12]; [@bib2]; [@bib28]). There is a worldwide increase in the incidence of PTC ([@bib20]; [@bib21]). Increase in the incidence of thyroid cancers could be partially attributed to the increased use of PET scans and Doppler thereby leading to early detection ([@bib41]; [@bib27]). Other contributing factors include radiation exposures, obesity, diet and lifestyle ([@bib29]). In Saudi Arabia, thyroid cancer is the most common malignancy among females after breast cancer and accounts for 7.4% of overall cancers and 10.6% of all female malignant neoplasm ([@bib3]; [@bib20]).

Follicular variant of papillary thyroid carcinoma (FVPTC) is the second most common histological subtype among PTCs. Although prognosis of FVPTC is not different from conventional phenotype ([@bib42]), there is increasing evidence that suggest FVPTC is composed of distinct biological entities ([@bib40]). Follicular variant of PTC have higher frequency of allelic loss of heterozygosity of tumour suppressor genes as compared with conventional PTCs ([@bib19]).

The phosphoinositol 3-kinase (PI3K) AKT signal transduction pathways contributes to tumourigenesis and survival, and is activated in many cancer types including thyroid cancer ([@bib7]; [@bib5]; [@bib11]; [@bib25]; [@bib31]). One of the main regulator of PI3K/AKT pathway is the phosphatase and tensin homolog deleted on chromosome 10 (PTEN) located at 10q23.3 which is a tumour suppressor gene that acts by negatively regulating the PI3K/AKT pathway ([@bib6]; [@bib14]).

The mechanism of PTEN inactivation can be attributed to several mechanisms such as point mutation ([@bib15]; [@bib35]), deletion ([@bib8]; [@bib24]), promoter hypermethylation ([@bib18]; [@bib30]) and post-translational modification ([@bib39]). Among post-translational modifications, phosphorylation is the dominant mechanism of PTEN modification ([@bib37]; [@bib36]). The molecular basis of PTEN inactivation in thyroid carcinogenesis is still not fully elucidated. Several reported mechanism of PTEN inactivation in thyroid cancer varies from deletion ([@bib10]), mutation ([@bib17]) to gene methylation ([@bib1]). However, the reported incidence of mutations in PTEN genes are low in papillary thyroid tumours ([@bib23]; [@bib33]). Deletion as well as loss of heterozygosity of the PTEN gene is suggested to have a greater role in thyroid carcinogenesis ([@bib10]; [@bib17]). Aberrant methylation causing silencing of the PTEN gene is also been known to enhance the signalling of PI3K/AKT pathway, contributing to the progression of thyroid tumours ([@bib18]). PTEN is hence considered an important tumour suppressor in thyroid carcinogenesis whose deficiency could lead to thyroid tumourigenesis ([@bib4]) and progression ([@bib18]).

Previous studies performed on thyroid cancer for the role of PTEN have been contradictory. One reason for this discordance can be attributed to small sample size. Therefore, we took the advantage of our existing large scale thyroid cancer TMA that includes more than 1000 PTC with follow-up data to investigate the incidence of PTEN alterations in Saudi PTC. PTEN loss was evaluated by IHC in TMA format and fluorescence *in situ* hybridisation (FISH) was used to assess the overall frequency of PTEN copy number change in PTC. PTEN alteration was studied for correlation with clinicopathological parameters and also for any impact on clinical outcome.

Material and methods
====================

Patient selection and tissue microarray construction
----------------------------------------------------

One thousand and forty patients with PTC diagnosed between 1988 and 2011 were selected from King Faisal Specialist Hospital and Research Centre. All PTCs were analysed in a tissue microarray (TMA) format. Clinical and histopathological data were available for all the patients. Long-term follow-up data were available for most of the patients. TMAs were constructed with two-fold redundancy from formalin-fixed, paraffin-embedded PTC specimens as described previously ([@bib22]). Tumour regions were mapped by a pathologist for coring. The TMA was constructed with 0.6 mm diameter cores spaced 0.8 mm apart using a tissue microarrayer (Semi automated Arrayer, CM1 Mirlacher, Neuenburg, Germany). The TMA block was cut into 5 *μ*m sections, adhered to a slide by an adhesive tape-transfer method (Instrumedics, Hackensack, NJ, USA) and UV cross-linked. The Institutional Review Board of King Faisal Specialist Hospital and Research Centre approved the study under Project RAC\# 206008 on PTC archival clinical samples.

Evaluation of histological subtypes
-----------------------------------

Histological subtypes were classified according to World Health Organization (2004) classification. Papillary carcinoma was diagnosed based on characteristic features such as nuclear enlargement, nuclear crowding, ground glass appearance, nuclear grooving and nuclear pseudoinclusions. Tall cell variant was diagnosed when tumour composed predominantly of tumour cells with height three times their width, nuclear features of papillary carcinoma and plentiful oxyphilic cytoplasm. Follicular variant of PTC was diagnosed when tumour composed entirely of follicles of different shapes and size with virtually no papillae formation and cells lining the follicles possessing nuclear features of papillary carcinoma.

Immunohistochemistry
--------------------

Standard protocol was followed for IHC staining. For antigen retrieval, Dako (Dako Denmark A/S, Glostrup, Denmark) Target Retrieval Solution pH 9.0 (Catalog number S2368) was used, and the slides were microwaved at 750 W for 5 min and then at 250 W for 20 min. Tissue microarray sections were stained with primary antibody PTEN (clone 6H2.1, Dako, 1:50 dilution, pH9) and p27 (clone 57, Invitrogen (Invitrogen Corporation, Carlsbad, CA, USA), 1:400 dilution, pH9). The Dako Envision Plus System kit was used as the secondary detection system with 3, 3′-diaminobenzidine as chromogen. All slides were counterstained with haematoxylin, dehydrated, cleared and mounted. Negative controls included omission of the primary antibody. Normal tissues of different organ system were also included in the TMA to serve as control. Only fresh cut slides were stained simultaneously to minimise the influence of slide aging and maximise reproducibility of the experiment. For immunoscoring of PTEN, only intensity score was taken into consideration (0--no staining, 1--weak, 2--moderate and 3--strong). Cases showing ⩾1+ intensity score was considered as positive for PTEN expression. Score 0 was considered as loss of PTEN expression. For p27, tumour cells showing staining of any intensity of ⩾1+ in ⩾50% of tumour cell was considered as positive.

Immunohistochemical scoring was done by two pathologists (SB and SP), blinded to the clinicopathological characteristics. Discordant scores were reviewed together to achieve agreement.

PTEN fluorescent *in situ* hybridisation
----------------------------------------

For PTEN, dual-colour FISH on paraffin-embedded TMA was performed using commercially available DNA probes LSI PTEN/CEP 10; Vysis Inc (Abbott Laboratories, Abbott Park, IL, USA). The PTEN locus-specific probe located on cytoband 10q23 was labelled with Spectrum Orange and centromere of chromosome 10 probe region 10p11.1-q11.1 was labelled with Spectrum Green (LSI PTEN/CEP 10; Vysis Inc.). The PTEN genomic probe spans 368 kb and starts 166 kb from 5′ end of the gene and extends 98 kb past the 3′ end of the gene. Histologic TMA tissue sections of 5 *μ*m thickness were deparaffinised with a series of xylene prior to immersion in 100% ethanol. Fluorescent *in situ* hybridisation was carried out according to the manufacturer\'s instructions.

The FISH analyses for PTEN were performed independently and without knowledge of the immunohistochemical result. The PTEN /CEP17 ratios were calculated as stated in the manufacturer\'s guidelines. A cell with two signals of green (centromere 10) and two signals of orange (PTEN) was considered as normal or a PTEN /CEP17 ratio of 1 was considered normal; a tumour cell with two green (centromere 10) and one orange signal (PTEN) with a ratio of 0.5 was considered a hemizygous deletion; a tumour cell with two green and total absence of orange signal (PTEN) and a ratio of 0 was considered a homozygous deletion.

Statistical analysis
--------------------

The JMP 10.0 (SAS Institute Inc., Cary, NC, USA) software package was used for data analyses. We examined the association of PTEN alterations with clinicopathological parameters, biomarker expression and also performed survival analysis. Survival curves were generated using Kaplan--Meier method with significance evaluated using the Mantel-Cox log-rank test. Values of *P*\<0.05 were considered statistically significant.

Results
=======

Clinicopathological features
----------------------------

The mean age of the patients at initial surgery was 40.4 years (range 6--92 years). Of the patients, 261 were (25.1%) males and 779 (74.9%) were females. The mean duration of follow-up was 76.5 months (range 0--280 months). A total of 791 (78.3%) tumours were classical papillary carcinomas; 153 (15.1%) were follicular variant of papillary thyroid carcinoma; and 66 (6.5%) were tall cell variant. Extrathyroidal extension was seen in 462 (52.9%) cases and American Joint Committee on Cancer staging was as follows: 693 (68.6%) stage I; 51 (5.1%) stage II; 84 (8.3%) stage III; and 182 (18.0%) stage IV.

PTEN expression and its correlation with clinicopathological parameters
-----------------------------------------------------------------------

Immunohistochemical analysis of PTEN expression was interpretable in 992 PTC spots, and the incidence of PTEN loss of expression in our cohort was found to be 24.5% (243 of 992 spots). Loss of PTEN expression was more frequently detected in the follicular variant (29.9%) compared with classical and tall cell variant of papillary carcinoma (24.8% and 9.7%, respectively; *P*=0.0039). Loss of PTEN expression correlated significantly with absence of extrathyroidal extension (*P*=0.0337) ([Table 1](#tbl1){ref-type="table"}).

In addition, the loss of PTEN expression showed a significant association with p27 loss on IHC (*P*=0.0272). However, PTEN expression was not associated with age, gender, lymphovascular invasion and AJCC stage. There was no difference in survival between patients showing PTEN loss and those tumours expressing the protein (*P*=0.2763) ([Figure 1](#fig1){ref-type="fig"}).

PTEN deletion on FISH and its correlation with clinicopathological parameters
-----------------------------------------------------------------------------

PTEN deletion by FISH was interpretable in 916 PTC spots, and the incidence of PTEN deletion in our cohort was only in 4.8% (44 of 916) of cases. PTEN deletion was significantly associated with old aged patients (above 45years) at the time of diagnosis (*P*=0.0253). No association was seen with any other clinical and pathological parameters ([Table 2](#tbl2){ref-type="table"}). We also could not find any statistical correlation between PTEN FISH deletion and protein loss by IHC. PTEN FISH deletion was not associated with any significant survival difference (*P*=0.9063) ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}).

Follicular variant of papillary thyroid cancer and its clinicopathological parameters
-------------------------------------------------------------------------------------

When we compared FVPTC with the more common classical papillary subtype of PTC, we found that FVPTC was significantly associated with absent extrathyroidal extension (*P*\<0.0001), smaller size (*P*=0.0142), stage (*P*=0.0014) and absence of regional lymph node metastasis (*P*\<0.0001). Strikingly, there was a significant positive association of FVPTC with distant metastasis (*P*=0.0026) ([Table 3](#tbl3){ref-type="table"}).

Discussion
==========

Well-differentiated papillary thyroid carcinoma (PTC) accounts for about 90% of all thyroid cancers. Although the majority of these tumours tend to behave as indolent lesions, a small percentage of PTCs are highly aggressive and result in disseminated systemic spread to distant sites ([@bib29]). In our attempt to define molecular markers that might help to identify either aggressive behaviour or certain types of PTC, we screened the frequency of PTEN alteration in a large cohort of more than thousand PTC in TMA format given that the inactivation can occur through a variety of mechanisms.

PTEN inactivation reflected by complete absence of PTEN by IHC was seen in 24.5% of our PTC cohort. Previous studies have reported differences in incidence of PTEN in different ethnic group which range from 29.7% ([@bib13]) in Caucasian to 52.6% in Asian population ([@bib26]). Our results were similar to the Caucasian population as compared with other ethnicities.

PTEN inactivation in our patient cohort was not correlated with aggressive clinical parameters like nodal metastasis and extrathyroid extension reported by others ([@bib26]). However, PTEN loss of expression in our cohort was found to be significantly associated with FVPTC. Although FVPTC tend to behave clinically similar to classical PTC, several studies have hypothesised that FVPTC may reflect aggressive parameters like distant metastasis, extrathyroid extension, bilateral lesions and vascular invasion at the time of diagnosis ([@bib16]). Our study has also shown association between FVPTC and distant metastasis when compared with the classical subtype. Therefore, inactivation of PTEN in this particular subtype of PTC could probably have several clinical implications as other studies have revealed the diagnostic and clinical challenges associated with FVPTC as its molecular features are shared by both papillary thyroid cancers and follicular neoplasms ([@bib32]; [@bib9]).

In our study, PTEN expression loss is found to be significantly correlated with loss of expression of cell cycle inhibitor p27, which might indicate that PTEN may have an important role in cell cycle regulation in PTC. These data are in concordance with another study that hypothesised PTEN suppressor gene is involved in upregulation of cell cycle inhibitor p27 ([@bib4]).

There are several mechanisms known for PTEN inactivation including gene deletion ([@bib10]), mutation ([@bib34]) and promoter methylation ([@bib38]). To test whether PTEN deletion might act as an important mechanism of PTEN inactivation, we have analysed PTEN deletion by FISH. Only 4.8% of our cohort showed PTEN gene deletion. No association seen between PTEN expression loss by IHC and PTEN deletion by FISH might indicate that PTEN gene deletion may not probably be the main mechanism for PTEN inactivation in Middle Eastern PTC. Even though PTEN promoter methylation leading to inactivation was not assessed in this study, lack of association between PTEN gene deletion and protein expression loss might strengthen the hypothesis that promoter methylation could be one of the main mechanism of PTEN inactivation. Our findings might pave the road for more studies to analyse the role of promoter methylation in PTEN inactivation in PTC.

In conclusion, PTEN loss is a common event in a subset of Middle Eastern PTC and gene deletion accounts for minority of PTEN protein expression loss. PTEN-mediated thyroid carcinogenesis have a greater role in FVPTC subtype. Lack of association between PTEN loss of protein expression and PTEN gene deletion might strengthen the hypothesis that PTEN inactivation in PTC is due to another mechanism such as promoter methylation rather than genomic alteration. Understanding the genetic landscape of these thyroid tumour subtypes will aid in accurately diagnosing, targeting and managing potential targets that have vital roles in PTC. Therefore, more studies are needed to understand the role of PTEN in PTC and mechanism behind its inactivation in this commonly occurring malignancy.
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![**Immunohistochemical analysis of PTEN and p27 in papillary thyroid carcinoma.** Tissue microarray spots showing expression of (**A**) PTEN and (**C**) p27. In contrast, different TMA spots showing loss of expression of (**B**) PTEN and (**D**) reduced expression of p27. Magnification ( × 20) on Olympus BX-51 microscope (Olympus America, Center Valley, PA, USA) with inset showing × 40 magnifications of the same TMA spot.](bjc2015169f1){#fig1}

![**(A) Papillary thyroid carcinoma TMA spot showing deletion of PTEN gene (single red PTEN 2 signals and two green signals represent the reference gene of two centromeres of chromosome 10).** Inset single cell. (**B**) Normal thyroid tissue spot showing no deletion (two red PTEN signals and two green centromeric signals). Inset single cell.](bjc2015169f2){#fig2}

![**Kaplan--Meier survival curves.** No significant survival difference was seen between patients showing PTEN protein expression loss and those expressing PTEN protein (**A**). Similarly, no significant survival difference was seen between patients showing PTEN deletion and those without deletion (**B**).](bjc2015169f3){#fig3}

###### Correlation of PTEN-IHC with clinico-pathological parameters in PTC

                                  **Total**   **PTEN expression**   **PTEN expression loss**                      
  ------------------------------ ----------- --------------------- -------------------------- ------ ----- ------ --------
  No. of patients                    992                                      749              75.5   243   24.5   
  **Age (years)**                                                                                                 
  ⩽45                                628             63.3                     469              74.7   159   25.3  0.4275
  \>45                               364             36.7                     280              76.9   84    23.1   
  **Sex**                                                                                                         
  Female                             744             75.0                     571              76.8   173   23.2  0.1186
  Male                               248             25.0                     178              71.8   70    28.2   
  **Extrathyroidal extension**                                                                                    
  Absent                             391             46.7                     284              72.6   107   27.4  0.0337
  Present                            446             53.3                     352              78.9   94    21.1   
  **pT**                                                                                                          
  pT1                                257             26.7                     184              71.6   73    28.4  0.2944
  pT2                                197             20.5                     156              79.2   41    20.8   
  pT3                                410             42.7                     313              76.3   97    23.7   
  pT4                                97              10.1                      73              75.3   24    24.7   
  **pN**                                                                                                          
  pN0                                377             40.9                     271              71.9   106   28.1  0.0582
  pN1                                544             59.1                     421              77.4   123   22.6   
  **Distant metastasis**                                                                                          
  M0                                 937             94.7                     708              75.6   229   24.4  0.9884
  M1                                 53               5.3                      40              75.5   13    24.5   
  **Stage**                                                                                                       
  I                                  658             68.3                     493              74.9   165   25.1  0.6231
  II                                 50               5.2                      39              78.0   11    22.0   
  III                                80               8.3                      56              70.0   24    30.0   
  IV                                 176             18.3                     136              77.3   40    22.7   
  **Histology type**                                                                                              
  Follicular variant                 144             15.0                     101              70.1   43    29.9  0.0039
  Papillary-classical                757             78.6                     569              75.2   188   24.8   
  Tall-cell variant                  62               6.4                      56              90.3    6    9.7    
  **Tumour focality**                                                                                             
  Multifocal                         462             49.8                     356              77.1   106   22.9  0.3869
  Unifocal                           465             50.2                     347              74.6   118   25.4   
  **p27**                                                                                                         
  Above 50%                          86               8.9                      73              84.9   13    15.1  0.0272
  Below=50%                          880             91.1                     657              74.7   223   25.3   
  **Disease-free survival**                                                                                       
  5 years                                                                                      77.4         77.3  0.2763

Abbreviations: IHC=immunochemistry; PTC=papillary thyroid carcinoma.

###### Correlation of PTEN FISH with clinico-pathological parameters in PTC

                                  **Total**   **PTEN Deleted**   **PTEN Normal/Gain**                      
  ------------------------------ ----------- ------------------ ---------------------- ------ ----- ------ --------
  No. of patients                    916                                  44            4.8    872   95.2   
  **Age (years)**                                                                                          
  ⩽45                                585            63.9                  21            3.6    564   96.4  0.0253
  \>45                               331            36.1                  23            6.9    308   93.1   
  **Sex**                                                                                                  
  Female                             687            75.0                  29            4.2    658   95.8  0.1671
  Male                               229            25.0                  15            6.6    214   93.4   
  **Extrathyroidal extension**                                                                             
  Absent                             360            46.9                  12            3.3    348   96.7  0.1209
  Present                            407            53.1                  23            5.6    384   94.4   
  **pT**                                                                                                   
  pT1                                235            26.6                  10            4.3    225   95.7  0.8318
  pT2                                191            21.6                  11            5.8    180   94.2   
  pT3                                372            42.1                  18            4.8    354   95.2   
  pT4                                86             9.7                   3             3.5    83    96.5   
  **pN**                                                                                                   
  pN0                                348            41.2                  18            5.2    330   94.8  0.2145
  pN1                                496            58.8                  17            3.4    479   96.6   
  **Distant metastasis**                                                                                   
  M0                                 868            95.0                  41            4.7    827   95.3  0.5965
  M1                                 46             5.0                   3             6.5    43    93.5   
  **Stage**                                                                                                
  I                                  609            68.7                  25            4.1    584   95.9  0.2271
  II                                 46             5.2                   1             2.2    45    97.8   
  III                                77             8.7                   7             9.1    70    90.9   
  IV                                 155            17.5                  9             5.8    146   94.2   
  **Histology type**                                                                                       
  Follicular variant                 133            15.0                  8             6.0    125   94.0  0.3504
  Papillary-classical                693            78.2                  30            4.3    663   95.7   
  Tall-cell variant                  60             6.8                   5             8.3    55    91.7   
  **Tumour focality**                                                                                      
  Multifocal                         429            50.1                  23            5.4    406   94.6  0.5316
  Unifocal                           428            49.9                  19            4.4    409   95.6   
  **p27**                                                                                                  
  Above 50%                          86             9.7                   5             5.8    84    94.2  0.5974
  Below=50%                          798            90.3                  36            4.5    762   95.5   
  **PTEN IHC**                                                                                             
  High (1--3)                        679            77.0                  31            4.6    648   95.4  0.8315
  Low (0)                            203            23.0                  10            4.9    193   95.1   
  **Disease-free survival**                                                                                
  5 years                                                                               80.6         77.6  0.9063

Abbreviations: IHC=immunochemistry; PTC=papillary thyroid carcinoma.

###### Correlation of FVPTC with classical papillary subtype in PTC

                                  **Total**   **Follicular Variant**   **Pap Classical Variant**                      
  ------------------------------ ----------- ------------------------ --------------------------- ------ ----- ------ ----------
  No. of patients                    944                                          153              16.2   791   83.8   
  **Age (years)**                                                                                                     
  ⩽45                                612               64.8                       99               16.0   514   84.0  0.8259
  \>45                               332               35.2                       55               16.6   277   83.4   
  **Sex**                                                                                                             
  Female                             709               75.1                       118              16.6   591   83.4  0.5251
  Male                               235               24.9                       35               14.9   200   85.1   
  **Extrathyroidal extension**                                                                                        
  Absent                             377               47.9                       92               24.4   285   75.6  \<0.0001
  Present                            410               52.1                       35               8.5    375   91.5   
  **pT**                                                                                                              
  pT1                                260               28.4                       41               15.8   219   84.2  0.0142
  pT2                                194               21.2                       45               23.2   149   76.8   
  pT3                                371               40.5                       48               12.9   323   87.1   
  pT4                                91                9.9                        11               12.1   80    87.9   
  **pN**                                                                                                              
  pN0                                361               41.3                       95               26.3   266   73.7  \<0.0001
  pN1                                512               58.7                       44               8.6    468   91.4   
  **Distant metastasis**                                                                                              
  M0                                 894               94.9                       136              15.2   758   84.8  0.0026
  M1                                 48                5.1                        16               33.3   32    66.7   
  **Stage**                                                                                                           
  I                                  639               69.7                       99               15.5   540   84.5  0.0014
  II                                 47                5.1                        18               38.3   29    61.7   
  III                                74                8.1                        12               16.2   62    83.8   
  IV                                 157               17.1                       19               12.1   138   87.9   
  **Tumour focality**                                                                                                 
  Multifocal                         436               49.6                       64               14.7   372   85.3  0.1303
  Unifocal                           444               50.4                       82               18.5   362   81.5   

Abbreviations: FVPTC=follicular variant of papillary thyroid carcinoma; PTC=papillary thyroid carcinoma.
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